The Antibody Development Facility provides Fred Hutchinson/University of Washington Cancer Consortium (Consortium) investigators with custom designed monoclonal and recombinant (scFv) antibodies. Intact monoclonal antibodies are produced via traditional hybridoma technology while recombinant antibodies are produced via phage display technology. Recombinant antibody fragments containing Vh and VI chains (scFvs) are derived by bio panning on the relevant antigen via both positive and negative panning techniques. Use of both of these technologies has permitted the identification antibodies useful for traditional biochemical, cell biological and immunological characterization of protein antigens, the creation of DNA vaccines, as well as high through put technologies useful for identification of antibodies directed to nonimmunogenic peptide antigens as well as biomarker discovery (scFv antibody arrays). This application requests continued support for a resource which continues to fulfill an essential role for research within the Consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-39
Application #
8561928
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$129,531
Indirect Cost
$49,409
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Gantt, Soren; Orem, Jackson; Krantz, Elizabeth M et al. (2016) Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. J Infect Dis 214:36-44
Cheng, Guang-Shing; Campbell, Angela P; Xie, Hu et al. (2016) Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 22:925-31
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Yu, Jeffrey; Storer, Barry E; Kushekhar, Kushi et al. (2016) Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol 34:2583-90
Cohen, Stacey A; Laurino, Mercy; Bowen, Deborah J et al. (2016) Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. Cancer 122:393-401
Mather, Cheryl A; Mooney, Sean D; Salipante, Stephen J et al. (2016) CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel. Genet Med 18:1269-1275
Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6
Martin, Paul J; Fan, Wenhong; Storer, Barry E et al. (2016) Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood 128:2450-2456
Song, Xiaoling; Schenk, Jeannette M; Diep, Pho et al. (2016) Measurement of Circulating Phospholipid Fatty Acids: Association between Relative Weight Percentage and Absolute Concentrations. J Am Coll Nutr 35:647-656
Santiago-Torres, Margarita; Kratz, Mario; Lampe, Johanna W et al. (2016) Metabolic responses to a traditional Mexican diet compared with a commonly consumed US diet in women of Mexican descent: a randomized crossover feeding trial. Am J Clin Nutr 103:366-74

Showing the most recent 10 out of 1027 publications